CHIRUTA, CHANDRAMOULI,BOLLU, VANKATAIAH,CAO, JIANGUO,EASTMAN, BRIAN WALTER,MITTAPALLI, GOPI KUMAR,MAK, CHI CHING,KC, SUNIL KUMAR
申请号：
ARP170101055
公开号：
AR108325A1
申请日:
2017.04.26
申请国别(地区):
AR
年份:
2018
代理人:
摘要：
In order to treat various diseases and diseases, isoquinolones were transmitted. More specifically, it refers to the use of isomerization or similar compounds in the treatment of disorders characterized by activation of Wnt road signals (e.g., cancer, abnormal cell proliferation, angioplasty, fibrous disorders), Bone, cartilage and osteopathy,Cell events are regulated by Wnt road signaling and genetic diseases, as well as neural conditions / diseases caused by mutations or deregulation of Wnt roads and / or one or more components of Wnt markers. Methods for treating Wnt related diseases are also provided. 1. Characteristic 1: acceptable salt (1) of a compound or a medicament contained in a formula,There: R1,R2,R83088 and r83099 are independent of the unreplaced Y - (c83218-83318323y-unreplaced Y - (c83213-833183323) - matrix)； R3 is a heterogeneous compound with five optional members, consisting of 1-4 r8308；； 83099；R8310 is selected from the group consisting of 1-5 cubic meters of substituted phenyl；-(c83218c83318323) - 8346； - substitute pyridine, substitute 1-6 r3-831183, substitute 6-10 pagan, substitute 1-6 r3-8311；wherein the carbonyl of formula (1) is attached to an aromatic ring of the heteroaryl； wherein the - (C₁₋₃ alkylene) is optionally substituted with one or more substituents defined anywhere else herein； each R³⁶ is independently selected from the group consisting of halide, - (unsubstituted C₁₋₉-alkyl), - (unsubstituted C₂₋₉-alkenyl), - (unsubstituted C₂₋₉-alkynyl), - (unsubstituted C₁₋₉-alkyl) substituted, -XR⁴²,-C (3DO) N (R)- (alkylene C₁₋₄) ₚ-N (R⁵⁰) ₂,- (C₁₋₄ alkylene) ₚ-heterocyclyl optionally substituted with 1-10 R⁴³ and - (C₁₋₄ alkylene) ₚ-carbocyclyl optionally substituted with 1-12 R⁴⁴；wherein each - (C₁₋₄ alkylene) is optionally substituted, independently, with one or more substituents defined anywhere else herein； each R³⁷ is independently selected from the group consisting of halide, - (unsubstituted C₁₋₉-alkyl), - (unsubstituted C₂₋₉-a
